MEDIATOR INFORMATION OUR DEVELOPMENT PORTFOLIO Updated September 2021 ONCOLOGY CARDIOMETABOLISM NEUROSCIENCE IMMUNO-INFLAMMATION PHASE 1 Haematological malignancies Mcl1 inhibitor Haematological malignancies Bcl2 inhibitor Haematological malignancies DHODH inhibitor Solid tumors Anti CD73 Solid tumors MAT2A inhibitor Solid tumors NKG2A Solid tumors PDLx41 BB Solid tumors Anti PD1xAnti TIM3 Relapsed or refractory myelodysplastic syndrome (MDS) Tibsovo® (pre-registration) Grade 2-3 Gliome, combo Vorasidenib PHASE 2 Sjögren disease Anti IL7R PHASE 3 Colorectal cancer, 1st line Combo Lonsurf® Colorectal cancer, 3rd line Combo Lonsurf® Colorectal cancer Anti EGFR combo Lonsurf® Acute myeloid leukemia (AML) IC-ineligible, 1st line Tibsovo® Acute myeloid leukemia (AML) IC-eligible, 1st line Tibsovo® Low-grade Glioma Vorasidenib TERMS OF USEDATA PRIVACYCOOKIE MANAGEMENTCONTACT USREPORT A SIDE EFFECT ©2020 SERVIER LABORATORIES We use cookies to improve your experience, produce audience statistics, offer you services tailored to your interests and provide features associated with social media. You can change your preferences at any time on the site. Accept all Change cookie settings Privacy policy

MEDIATOR INFORMATION REPORT A SIDE EFFECT Our Group’s commitment is to continuously ensure the quality of our products, and the monitoring of side effects and any risk situation that may affect patient safety. If you noticed or if you think you may have a health problem related to a Servier medicine or any other Servier health product, you can contact us at any time and report it to us by filling out the form below. In France, you can also report any side effect to your health authority (ANSM) by clicking here. For other countries, please contact your local health authority. ATTACH A FILE *Required fields TERMS OF USEDATA PRIVACYCOOKIE MANAGEMENTCONTACT USREPORT A SIDE EFFECT ©2020 SERVIER LABORATORIES